Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: Newsfilter
Palvella Therapeutics Presentations: Palvella Therapeutics will present two posters at the 12th Pediatric Dermatology Research Alliance Annual Conference, showcasing data on QTORIN™ rapamycin as a potential treatment for microcystic lymphatic malformations and details from the Phase 3 SELVA study.
QTORIN™ Platform Overview: The QTORIN™ platform aims to develop localized therapies for rare genetic skin diseases, with QTORIN rapamycin being the lead candidate currently in clinical trials, having received multiple FDA designations for its potential efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
